Shankar Musunuri, PhD

The chairman, chief executive officer, and cofounder of Ocugen discussed programs including OCU400 and OCU410.

The chairman, chief executive officer, and cofounder of Ocugen discussed the recent data update on the company’s OCU400 program in inherited retinal diseases.

The chairman, chief executive officer, and cofounder of Ocugen discussed unmet needs within retinitis pigmentosa and the potential of OCU400 gene therapy.